Lilly begins Foundayo's first big consumer ad campaign, fronted by Martha Stewart

Eli Lilly began a wide direct-to-consumer advertising campaign for Foundayo, its brand name for the pill orforglipron, in late August 2026, with Martha Stewart as the campaign's face. The ads quickly drew criticism in online consumer forums, where a Reddit thread titled "Martha Stewart is shilling weight loss meds now" captured pushback over reports that Stewart does not personally take a GLP-1 medicine ^[1]. The full text of that discussion was not accessible for this story, so the specific complaints raised by commenters beyond the headline are not confirmed ^[1].

The campaign arrives as Foundayo has become a meaningful part of Lilly's business. In its second-quarter 2026 earnings release, dated August 5, 2026, Lilly listed Foundayo among its official "Key Products" for the first time, reporting $98 million in revenue for the drug in the quarter it was added, with no prior-year comparison available ^[2]. Company-wide, Lilly's marketing, selling, and administrative expenses rose 25% to $3.4 billion in the quarter, which Lilly attributed to "promotional efforts supporting ongoing and planned launches" — a category that would include a product like Foundayo moving into wider marketing ^[2].

Lilly's release also shows regulatory activity around orforglipron continuing alongside the ad push. The company said it submitted orforglipron for type 2 diabetes in the U.S. during the second quarter of 2026 ^[2], separate from its existing marketing as Foundayo for weight management. The earnings release does not detail Foundayo's obesity approval history or its list price, so those specifics are not confirmed in the sources reviewed here.

The development summary states that Lilly's leadership had told analysts broad DTC marketing would wait until Foundayo had commercial access across the three major U.S. pharmacy benefit managers, and that this access was secured in June 2026. That specific claim about PBM coverage and the analyst commentary is not present in the Lilly earnings release or the Reddit thread available for this story, so it remains unconfirmed by the sources reviewed and should be treated as not yet independently verified.

Why it matters for patients

A large celebrity-fronted ad campaign generally signals that a drugmaker believes insurance coverage and pharmacy access have reached a point where mass marketing makes sense, since ads that reach people who cannot get the drug covered are less useful to the company. Lilly's own numbers show Foundayo generating real revenue in its first quarter as a listed "Key Product," suggesting the company is scaling up distribution ^[2].

For patients, celebrity endorsements do not indicate personal experience with a drug unless a company says so, and questions raised online about whether Stewart uses a GLP-1 medicine herself reflect a broader pattern of scrutiny around weight-loss drug marketing ^[1]. Patients considering Foundayo should know that its price, specific insurance coverage terms, and full approval history are not detailed in the sources available for this story, meaning cost and coverage can vary and are not fully described here.

What happens next

Lilly's second-quarter release also flagged that a fuller data package for its other obesity drug candidate, retatrutide, is complete, with a Biologics License Application planned for the first quarter of 2027 ^[2]. No specific date was given in the sources for when the orforglipron type 2 diabetes submission might receive an FDA decision, and no timeline was provided for the scope or duration of the Foundayo advertising campaign itself ^[2].